Padagis US LLC: Drug Recall

Recall #D-0464-2023 · 02/21/2023

Class III: Low Risk

Recall Details

Recall Number: D-0464-2023
Classification: Class III
Product Type: Drug
Recalling Firm: Padagis US LLC
Status: Ongoing
Date Initiated: 02/21/2023
Location: Minneapolis, MN, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 43,238 cartons

Reason for Recall

Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point.

Product Description

Evamist (estradiol transdermal spray), 1.53 mg of estradiol per spray, 0.27 fl oz (8.1 mL) per metered-dose pump, Rx Only, Manufactured by DPT Laboratories, Ltd San Antonio, TX 78215, Manufactured for: Perrigo, Allegan, Minnapolis, MN 55427, NDC: 0574-2067-27

Distribution Pattern

Nationwide in the USA

Other Recalls by Padagis US LLC

Class II: Risk 02/06/2025

Defective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.
Class III: Low Risk 10/11/2024

Subpotent and Superpotent Drug. Out of specification assay results recorded as part of Uniformity of Container test during long-term stability testing.
Class II: Risk 11/01/2023

Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules
Class II: Risk 09/28/2023

Incorrect Product Formulation: Hydrophilic Colloidal Silica was used to manufacture the product rather than Hydrophobic Colloidal Silica as required by the manufacturing process.
Class II: Risk 08/17/2022

CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.

View all recalls by Padagis US LLC →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.